Skip to content Skip to navigation

In developing new drugs for rare diseases, this non-profit steps in when pharmaceutical companies won't

close up of an assortment of unmarked capsule-shaped and round pills of different colors
STOCK PHOTO/Getty Images
Jan 5 2019
Fellow, Research, Stanford, Students

A research team has reason to celebrate after the Food and Drug Administration granted it approval on Friday to begin a clinical trial for a new pediatric brain cancer drug, one that might have ended up overlooked by pharmaceutical companies.

The lead researcher on the team, Dr. Teresa Purzner has already beat impossible odds. The neurosurgeon and mom of three managed to get the approval in record time and with little money thanks to the help of a team of ‘scientific altruists’ called SPARK.

Dr. Teresa Purzner is a 2015 Bio-X Stanford Interdisciplinary Graduate Fellow.

Read the full article